People · Operator
Named in public records as an officer, director or promoter · active 2018–2020 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Fulcrum Therapeutics, Inc. | — | Biotechnology | Series C | $183.2M | $2.8B | 2018 |
Kate Haviland at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Kate Haviland on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Mark Levin | 1 | 9 |
| James Collins | 1 | 8 |
| James Tananbaum | 1 | 6 |
| Alan Ezekowitz | 1 | 4 |
| James Geraghty | 1 | 3 |
| Robert Gould | 1 | 3 |
| Bryan Stuart | 1 | 2 |
| Katina Dorton | 1 | 2 |
| Diego Cadavid | 1 | 1 |
| Owen Wallace | 1 | 1 |
| Amit Hasija | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.